Donato Koyalta1,2, Ralph-Sydney Mboumba Bouassa3,4, Almoustapha Maiga5, Aliou Balde6, Jules Bashi Bagendabanga7, Almahdy Ag Alinity8, David Veyer4, Hélène Péré4, Laurent Bélec4. 1. Centre Hospitalo-Universitaire Gabriel Touré, Bamako, Bamako, Mali. koyaltad@yahoo.fr. 2. Faculté des Sciences de la Santé Humaine de N'Djamena, N'Djamena, Chad. koyaltad@yahoo.fr. 3. Ecole Doctorale Régionale en Infectiologie Tropicale, Franceville, Gabon. 4. Laboratoire de Virologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, and Université de Paris, Paris, France. 5. Laboratoire du Centre Hospitalo-Universitaire Gabriel Touré, Bamako, Mali. 6. Pierre Louis Institute of Epidemiology and Public Health (IPLESP), Sorbonne University, INSERM, Paris, France. 7. Project Linkages - Family Health International, Bamako, Mali. 8. Clinique Soutoura, Bamako, Mali.
Abstract
BACKGROUND: High-risk human papillomavirus (HR-HPV) anal infection is a major problem among men who have sex with men (MSM) living in sub-Saharan Africa. The prevalence of anal HR-HPV infection and associated risk factors were estimated in a cross-sectional study in MSM living in Bamako, Mali. METHODS: MSM consulting at sexual health center of the National NGO Soutoura, Bamako, were prospectively included. Sociodemographic and clinical-biological data were collected. HPV detection and genotyping were performed from anal swabs using multiplex real-time PCR. Risk factors associated with anal HPV infection were assessed by logistic regression analysis. RESULTS: Fifty MSM (mean age, 24.2 years; range, 18-35) of which 32.0% were infected with HIV-1, were prospectively included. The overall prevalence of anal HPV infection of any genotypes was 70.0% (35/50) with 80.0% (28/35) of swabs positive for HR-HPV. HR-HPV-58 was the most detected genotype [13/35 (37.1%)], followed by HR-HPV-16 and low-risk (LR)-HPV-6 [12/35 (34.2%)], LR-HPV-40 [10/35 (28.6%)], LR-HPV-11 [9/35 (25.7%)], HR-HPV-51 [8/35 (22.8%)], HR-HPV types 18 and 39 [7/35 (20.0%)] and LR-HPV-43 [6/35 (17.1%)]. HR-HPV-52 and LR-HPV-44 were detected in lower proportions [5/35 (14.3%) and 4/35 (11.4%), respectively]. LR-HPV-42, LR-HPV-54, HR-HPV-31 and HR-HPV-35 were detected in very low proportions [3/35 (8.5%)]. Multiple HR-HPV infections were diagnosed in one-third of anal samples [16/50 (32.0%)], including around half of HR-HPV-positive anal swabs [16/35 (45.7%)]. More than half [27/50 (54.0%)] swabs were infected by at least one of HPV genotypes targeted by Gardasil-9® vaccine, including a majority of vaccine HR-HPV [22/50 (44.0%)]. In multivariate analysis, participation to sex in group was associated with anal infection by multiple HPV (aOR: 4.5, 95% CI: 1.1-18.1%; P = 0.032), and HIV-1 infection was associated with anal shedding of multiple HR-HPV (aOR: 5.5, 95% CI: 1.3-24.5%; P = 0.024). CONCLUSIONS: These observations indicate that the MSM community living in Bamako is at high-risk for HR-HPV anal infections, with a unique epidemiological HPV genotypes profile and high prevalence of anal HPV covered by the Gardasil-9® vaccine. Scaling up prevention strategies against HPV infection and related cancers adapted to this highly vulnerable MSM community should be urgently prioritized with innovative interventions.
BACKGROUND: High-risk human papillomavirus (HR-HPV) anal infection is a major problem among men who have sex with men (MSM) living in sub-Saharan Africa. The prevalence of anal HR-HPV infection and associated risk factors were estimated in a cross-sectional study in MSM living in Bamako, Mali. METHODS: MSM consulting at sexual health center of the National NGO Soutoura, Bamako, were prospectively included. Sociodemographic and clinical-biological data were collected. HPV detection and genotyping were performed from anal swabs using multiplex real-time PCR. Risk factors associated with anal HPV infection were assessed by logistic regression analysis. RESULTS: Fifty MSM (mean age, 24.2 years; range, 18-35) of which 32.0% were infected with HIV-1, were prospectively included. The overall prevalence of anal HPV infection of any genotypes was 70.0% (35/50) with 80.0% (28/35) of swabs positive for HR-HPV. HR-HPV-58 was the most detected genotype [13/35 (37.1%)], followed by HR-HPV-16 and low-risk (LR)-HPV-6 [12/35 (34.2%)], LR-HPV-40 [10/35 (28.6%)], LR-HPV-11 [9/35 (25.7%)], HR-HPV-51 [8/35 (22.8%)], HR-HPV types 18 and 39 [7/35 (20.0%)] and LR-HPV-43 [6/35 (17.1%)]. HR-HPV-52 and LR-HPV-44 were detected in lower proportions [5/35 (14.3%) and 4/35 (11.4%), respectively]. LR-HPV-42, LR-HPV-54, HR-HPV-31 and HR-HPV-35 were detected in very low proportions [3/35 (8.5%)]. Multiple HR-HPV infections were diagnosed in one-third of anal samples [16/50 (32.0%)], including around half of HR-HPV-positive anal swabs [16/35 (45.7%)]. More than half [27/50 (54.0%)] swabs were infected by at least one of HPV genotypes targeted by Gardasil-9® vaccine, including a majority of vaccine HR-HPV [22/50 (44.0%)]. In multivariate analysis, participation to sex in group was associated with anal infection by multiple HPV (aOR: 4.5, 95% CI: 1.1-18.1%; P = 0.032), and HIV-1 infection was associated with anal shedding of multiple HR-HPV (aOR: 5.5, 95% CI: 1.3-24.5%; P = 0.024). CONCLUSIONS: These observations indicate that the MSM community living in Bamako is at high-risk for HR-HPV anal infections, with a unique epidemiological HPV genotypes profile and high prevalence of anal HPV covered by the Gardasil-9® vaccine. Scaling up prevention strategies against HPV infection and related cancers adapted to this highly vulnerable MSM community should be urgently prioritized with innovative interventions.
Authors: Rebecca G Nowak; Patti E Gravitt; Xin He; Sosthenes Ketende; Wuese Dauda; Helen Omuh; William A Blattner; Manhattan E Charurat Journal: Sex Transm Dis Date: 2016-04 Impact factor: 2.830
Authors: Andrea L Wirtz; Gift Trapence; Dunker Kamba; Victor Gama; Rodney Chalera; Vincent Jumbe; Rosemary Kumwenda; Marriam Mangochi; Stephane Helleringer; Chris Beyrer; Stefan Baral Journal: Lancet HIV Date: 2017-02-28 Impact factor: 12.767
Authors: Saverio G Parisi; Mario Cruciani; Renzo Scaggiante; Caterina Boldrin; Samantha Andreis; Federico Dal Bello; Silvana Pagni; Andrea Barelli; Andrea Sattin; Carlo Mengoli; Giorgio Palù Journal: BMC Infect Dis Date: 2011-05-25 Impact factor: 3.090
Authors: Katharine J Looker; Amalia S Magaret; Katherine M E Turner; Peter Vickerman; Sami L Gottlieb; Lori M Newman Journal: PLoS One Date: 2015-01-21 Impact factor: 3.240
Authors: Susanne Hartwig; Jean Lacau St Guily; Géraldine Dominiak-Felden; Laia Alemany; Silvia de Sanjosé Journal: Infect Agent Cancer Date: 2017-04-11 Impact factor: 2.965
Authors: Chang Hun Lee; Sun Hee Lee; Shinwon Lee; Heerim Cho; Kye-Hyung Kim; Jung Eun Lee; Eun Ju Jung; Su Jin Lee; Eun Jung Kim; Ki Hyung Kim; Eunsoo Moon; Hong Je Cho Journal: PLoS One Date: 2016-08-22 Impact factor: 3.240
Authors: Etienne E Müller; Kevin Rebe; Tobias F Chirwa; Helen Struthers; James McIntyre; David A Lewis Journal: BMC Infect Dis Date: 2016-08-22 Impact factor: 3.090
Authors: Joanna Katarzyna Strzelczyk; Krzysztof Biernacki; Jadwiga Gaździcka; Elżbieta Chełmecka; Katarzyna Miśkiewicz-Orczyk; Natalia Zięba; Janusz Strzelczyk; Maciej Misiołek Journal: Diagnostics (Basel) Date: 2021-11-24